Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Decreases By 35.9%
by Danessa Lincoln · The Markets DailyBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) saw a significant drop in short interest in July. As of July 15th, there was short interest totaling 31,208,457 shares, a drop of 35.9% from the June 30th total of 48,685,241 shares. Based on an average daily volume of 5,245,936 shares, the days-to-cover ratio is currently 5.9 days. Approximately 12.8% of the company’s stock are short sold.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on BCRX shares. Cantor Fitzgerald upped their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. Wedbush dropped their price objective on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Citizens Jmp lifted their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Needham & Company LLC reduced their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Finally, Royal Bank Of Canada upped their target price on shares of BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.80.
Check Out Our Latest Research Report on BCRX
BioCryst Pharmaceuticals Stock Down 2.8%
Shares of NASDAQ BCRX opened at $8.98 on Friday. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.22. The stock’s 50 day moving average price is $9.30 and its 200-day moving average price is $8.63. The company has a market capitalization of $2.28 billion, a PE ratio of -5.04 and a beta of 0.55.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The business had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business’s revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.20 earnings per share. As a group, research analysts expect that BioCryst Pharmaceuticals will post -2.58 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth $123,452,000. Deerfield Management Company L.P. boosted its holdings in shares of BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after buying an additional 7,477,000 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of BioCryst Pharmaceuticals by 7,807.2% in the 4th quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock worth $57,791,000 after buying an additional 7,310,745 shares during the last quarter. Perceptive Advisors LLC grew its position in BioCryst Pharmaceuticals by 135.1% during the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after buying an additional 4,271,504 shares during the period. Finally, Bank of America Corp DE grew its position in BioCryst Pharmaceuticals by 231.6% during the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock valued at $48,474,000 after buying an additional 3,556,208 shares during the period. Institutional investors own 85.88% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.
The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.